Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z.
Bradley RH, National Institute of Child Health and Human Development (NICHD) Early Child Care Research Network, McLeod LD. Child care and common communicable illnesses in children aged 37 to 54 months. Arch Pediatr Adolesc. 2003 Feb;157(2):196-200. doi: 10.1001/archpedi.157.2.196